Showing results (61-70 of 233) with videos related to

Sort By:
Pageof 24
Inorganic Chemistry|October 27, 2007
Synthesis, X-ray, and electronic structures of a new nickel dibromide complex. Activity in the regioselective catalyzed dimerization of ethylene into 1-buteneGuilhem Mora, Steven van Zutphen, Christian Klemps, et al.
Nutrition and Cancer|May 4, 2007
Differential expression of genes induced by resveratrol in human breast cancer cell linesLudovic Le Corre, Nasséra Chalabi, Laetitia Delort, et al.
Plos One|July 9, 2011
Regulation of LRRK2 expression points to a functional role in human monocyte maturationJonathan Thévenet, Rosanna Pescini Gobert, Robertus Hooft van Huijsduijnen, et al.
Oncotarget|September 23, 2016
Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancerAbderrahim El Guerrab, Mahchid Bamdad, Fabrice Kwiatkowski, et al.
Breast Cancer Research and Treatment|January 12, 2012
Molecular insights on basal-like breast cancerMev Dominguez Valentin, Sabrina Daniela da Silva, Maud Privat, et al.
Anticancer Research|December 26, 2012
Genistein and daidzein: different molecular effects on prostate cancerMawussi Adjakly, Marjolaine Ngollo, Jean-Paul Boiteux, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|May 2, 2002
Expression of BRCA1 and BRCA2 in different tumor cell lines with various growth statusCécile Vissac, Monique Peffault De Latour, Yves Communal, et al.
Cellular Oncology (Dordrecht, Netherlands)|September 23, 2015
Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkersInsaf Fkih M'hamed, Maud Privat, Flora Ponelle, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|May 12, 2011
Peripheral blood DNA methylation detected in the BRCA1 or BRCA2 promoter for sporadic ovarian cancer patients and controlsRémy Bosviel, Emilie Michard, Guillaume Lavediaux, et al.
Trials|October 23, 2016
BRACAVENIR - impact of a psychoeducational intervention on expectations and coping in young women (aged 18-30 years) exposed to a high familial breast/ovarian cancer risk: study protocol for a randomized controlled trialFabrice Kwiatkowski, Pascal Dessenne, Claire Laquet, et al.
Pageof 24